Amylyx Pharmaceuticals: Phase 3 Breakthrough Triggers Stock Rally! Amylyx Ahead of FDA Approval for Avexitide!

The "Healthcare" sector proves to be a profitable sector in the current environment with nearly 6.5%. The "Drug Manufacturers - Specialty & Generic" area is considered to be very volatile. Recently, Amylyx Pharmaceuticals saw a strong rise of 89.62% in just one month. Which publications justify this high increase? Amylyx Pharmaceuticals focuses on rare diseases Avexitide reduced hypoglycemia by 55% in the Phase 3 study LUCIDITY Stock jumps 64% thanks to planned FDA filing Amylyx Pharmaceuticals Inc. (AMLX) is a biotechnology...